Investor Alert

Nov. 4, 2020, 4:27 p.m. EST

Top Penny Stocks To Watch Before Friday; 5 Biotech Stocks To Know

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Nov 04, 2020 (Penny Stocks via COMTEX) -- Top Biotech Penny Stocks To Watch Right Now

Are top biotech penny stocks on your watch list right now? If not, you may want to take a look at the industry. Over the last two days, one of the small cap stocks , Aptevo Therapeutics Inc. ( APVO Stock Report ) began captivating day traders across the market. The reason behind it has a lot to do with what we've seen as far as sympathy trading trends. If you recall, a few weeks ago, day traders were focusing on renewable energy stocks. Then it was electric vehicle stocks. In late October, there was a slew of low float penny stocks with a relationship to businesses in China. Is this the week we start seeing biotech penny stocks take off?

[Read More] Could These 4 Biotech & Psychedelic Stocks See Bullish Interest in 2020?

While time will tell, it's clear that attention is on biotech stocks. Aptevo specifically deals with immuno-oncology therapeutics. Yes, cancer treatment stocks are back in the spotlight. For Aptevo, the company announced that, based on preliminary data, a patient in cohort 6 of the clinical trial showed complete remission.

Now, whether we see a focus on immunotherapy stocks or a broader biotech focus, this could be something of note before Friday. So, heading into the rest of election week, here are 5 biotech penny stocks to watch .

Biotech Penny Stocks To Watch:

  1. GT Biopharma Inc. ( GTBP Stock Report )

  2. Corbus Pharmaceuticals Holdings Inc. ( CRBP Stock Report )

  3. BioDelivery Sciences ( BDSI Stock Report )

  4. GlycoMimetics Inc. ( GLYC Stock Report )

  5. PDS Biotechnology Corporation ( PDSB Stock Report )

Biotech Penny Stocks To Watch #1: GT Biopharma Inc.

GT Biopharma Inc. is one of the immunotherapy stocks that've gained interest over the last few weeks. Mainly for its TriKE treatment platform, GT has continued making progress on several fronts. TriKE(TM) is a combination protein that bridges an immune cell and a tumor cell to drive tumor cell killing power exponentially. It has led to new first-in-human phase studies to treat acute myeloid leukemia via GTB-3550.

The company recently completed treatment of the first patient enrolled at Dose Level 3 in its GTB-3550 TriKE(TM) Phase I/II clinical trial. In short, the findings showed promise including a noticeable decrease in AML blast levels. There was also an improvement in platelet and red blood cells numbers. Interim results were also chosen for inclusion for presentation at the American Society of Hematology Annual Meeting. What's more, is that GTB-3550 isn't the only thing that TriKE is being utilized in. The company has continued expanding upon several new initiatives.

A recent publication in the journal Cancers also expanded upon TriKE's potential. The company said that this specific a B7H3-targeted TriKE(TM) "has the potential to enhance natural killer cell immunotherapy in solid tumor settings". Furthermore it supported its further clinical development.

Biotech Penny Stocks To Watch #2: Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc.has been trying to recover after plummeting back in September. Corbus reported no significant differences in primary and secondary endpoints for its Phase 3 lenabasum study. This is the company's utaneous systemic sclerosis treatment candidate.

Aside from these data, what could have CRBP in the spotlight is its relationship to cannabis. We all know marijuana penny stocks are on the rise after recent legislative moves in the U.S. Furthermore, big news from Aphria ( APHA Stock Report ) entering the U.S. market via the acquisition of Sweetwater Brewing Company has traders looking for sympathy trades. Corbus' lenabasum, is an oral, selective cannabinoid receptor type 2 agonist that resolves chronic inflammation. We'll have to see if Wednesday's sympathy momentum carries through the rest of the week.

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.